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INTRODUCTION
In the recent years at the Department of Synthesis and Technology of Drugs, a number of fused derivatives of triazepine has been synthesized [11, 13] .
The synthetic derivatives of triazepine form various and important group of medicines. In the search for new structures with potential pharmacological activity, a set of novel imidazo [1,2-a] [1, 3, 5] triazepines has been obtained. Some known derivatives of imidazotriazepine show activity as muscle relaxants [1] , the others have antifungal [8] , anti-diabetic [3, 9, 10] , antimicrobial [2, 4, 5] , antiviral [7, 14] , anticancer [7] and analgesic [6] properties. This heterocyclic system has been obtained by us in a two-step reaction. It seemed worthwhile to synthesize new imidazo [1,2-a] [1, 3, 5] triazepine derivatives to estimate their pharmacological activity. [6, 12] with diethyl oxalic acid ester. The reaction was conducted in the boiling temperature of the solvent. The reaction sequence leading to the formation of small molecules (I-V) is outlined in Scheme 1.
MATERIALS AND METHODS

General
Melting points were determined on a Boetius apparatus and given uncorrected. The 1 H NMR spectra were recorded on AVANCE 300 MHz spectrometers stiffy Brucer in DMSO-d 6 as an internal standard. Elemental analyses were performed on a Perkin-Elmer analyzer. All the compounds were recrystallized from propan-2-ol. Chemicals for synthesis were purchased from Merck Co or Fluka Lab. and used without purification. Purity of the compounds was checked by thin layer chromatography (TLC).TLC was performed on commercial Merck SiO 2 plates with chloroform-methanol (10:2) solvent system and visualization under UV light at 254 nm.
The physical data of new compounds are shown in Table 1 , whereas their spectral data are provided underneath Table 1. 
ACKNOWLEDGMENTS
The paper was developed using the equipment purchased within the Project. The equipment of innovative laboratories doing research on new medicines used in the therapy of civilization and neoplastic diseases" within the Operational Program Development of Eastern Poland 2007-2013, Priority Axis I Modern Economy, Operations I.3 Innovation Promotion.
